Our FREE email course is here to save the day
Demonstrating that tirzepatide offers superior glycemic control and weight reduction compared to other covered GLP-1 agents strengthens the medical necessity argument
For some patients this may not be practical, and currently there are no data regarding the efficacy of oral semaglutide with dosing conditions (e.g., different times or fasting periods) other than those used in the PIONEER trials
The earlier 12-week Phase 2a trial had shown encouraging results (2.6 kg vs 0.8 kg for placebo), but the larger, longer, better-powered trial reversed that finding
Tirzepatide and Wegovy both offer powerful tools to help patients achieve better health outcomes
Often discussed together as a synergistic pairing, these two growth hormone secretagogues compounds that stimulate the release of growth hormone have attracted significant interest from researchers, clinicians, and patients seeking alternatives to synthetic human growth hormone (HGH)